Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 24, 2015 10:17 PM ET


Company Overview of Kadmon Corporation, LLC

Company Overview

Kadmon Corporation, LLC discovers and develops therapeutic drugs based on molecular biology and genomics for the treatment of oncology, immunology, and infectious and neurodegenerative diseases. The company also distributes and markets a portfolio of branded and generic drugs for the treatment and management of hepatitis C. Its products include Ribasphere, Ribasphere RibaPak, and Syprine. Kadmon Corporation, LLC was formerly known as Kadmon Holdings, LLC. The company was incorporated in 2009 and is based in New York, New York with operations in Warrendale, Pennsylvania; Wilmington, Massachusetts; and Monmouth Junction, New Jersey.

450 East 29th Street

5th Floor

New York, NY 10016

United States

Founded in 2009





Key Executives for Kadmon Corporation, LLC

Chief Executive Officer, President, and Member of the Board of Managers
Age: 62
Founder, Chief of Innovation, Science and Strategy, and Chairman of the Board
Age: 67
Chief Financial Officer
Executive Vice President of Biologics and President of Kadmon China
Chief Administrative, Compliance and Legal Officer, Executive Vice President, and General Counsel
Compensation as of Fiscal Year 2015.

Kadmon Corporation, LLC Key Developments

Kadmon Corporation, LLC Signs License Agreement with Nantong Jinghua Pharmaceutical Co., Ltd

Kadmon Corporation, LLC has signed a license agreement with Nantong Jinghua Pharmaceutical Co. Ltd. to discover, develop and commercialize Kadmon's human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for China. EGFR2 and PD-L1 monoclonal antibodies are used in the treatment of cancer. Under the terms of the agreement, Kadmon has received a $10 million equity investment from Jinghua and has the potential to receive more than $40 million upon the achievement of key milestones as well as 10% royalties on future net sales.

Kadmon Corporation, LLC Presents at 14th Annual BIO Investor Forum, Oct-20-2015 08:00 AM

Kadmon Corporation, LLC Presents at 14th Annual BIO Investor Forum, Oct-20-2015 08:00 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.

Kadmon Corporation, LLC Presents at Boston Biotech Conferences 2015, Nov-11-2015

Kadmon Corporation, LLC Presents at Boston Biotech Conferences 2015, Nov-11-2015. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States. Presentation Date & Speakers: Nov-11-2015, Samuel D. Waksal, Founder, Chief of Innovation, Science and Strategy, and Chairman of the Board. Nov-12-2015.

Similar Private Companies By Industry

Company Name Region
RiboNova Inc. United States
Easel Biotechnologies, LLC United States
Satori Pharmaceuticals Incorporated United States
ADMET Technologies, Inc. United States
IDM, Inc. United States

Recent Private Companies Transactions

Private Placement
October 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kadmon Corporation, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at